Nasal delivery of nanosuspension-based mucoadhesive formulation with improved bioavailability of loratadine: Preparation, characterization, and in vivo evaluation

Int J Pharm. 2020 Apr 15:579:119166. doi: 10.1016/j.ijpharm.2020.119166. Epub 2020 Feb 19.

Abstract

The unique requirements of poorly water-soluble drug delivery have driven a great deal of research into new formulations and routes of administration. This study investigates the use of nanosuspensions for solubility enhancement and drug delivery. Simple methods were used to prepare nasal formulations of loratadine based on nanosuspension pre-dispersion with sodium hyaluronate as a mucoadhesive agent. The nanosuspension was prepared by antisolvent precipitation method followed by ultrasonication and characterized for particle size, polydispersity index, zeta potential, morphology, and structure. Moreover, the nasal formulations were characterized for drug loading, pH, particle size, viscosity, bioadhesive viscosity parameter, and were evaluated for in vitro dissolution and diffusion, in addition to in vivo studies in a rat model. Loratadine nanosuspension displayed a particle size of 311 nm, a polydispersity index of 0.16, and zeta potential of -22.05 mV. The nanosuspension preserved the crystalline status of the raw drug. The addition of sodium hyaluronate exhibited an increase in the mean particle size and zeta potential of the nanoparticles. The nasal formulations showed enhanced bioadhesive properties compared to the unprocessed loratadine in the reference samples. The nanosuspension based-formulation that contained 5 mg mL-1 sodium hyaluronate and 2.5 mg mL-1 loratadine (NF4) showed a significant enhancement of flux and permeability coefficient through a synthetic membrane. NF4 exhibited 24.73 µg cm-2 h-1 and 0.082 cm h-1, while the reference sample showed 1.49 µg cm-2 h-1 and 0.017 cm h-1, for the flux and the permeability coefficient, respectively. Nasal administration of NF4 showed a bioavailability of 5.54-fold relative to the oral administration. The results obtained in this study indicate the potential of the nasal route and the nanosuspension for loratadine delivery. The relative bioavailability of NF4 was 1.84-fold compared to unprocessed loratadine in the reference sample. Therefore, the nanosized loratadine could be suggested as a practical and simple nanosystem for the intranasal delivery with improved bioavailability.

Keywords: Bioavailability; Loratadine; Mucoadhesive formulation; Nanosuspensions; Nasal delivery; Permeability.

Publication types

  • Comparative Study

MeSH terms

  • Adhesives / administration & dosage
  • Adhesives / chemistry*
  • Administration, Intranasal
  • Administration, Oral
  • Animals
  • Biological Availability
  • Drug Compounding / methods*
  • Drug Delivery Systems / methods*
  • Drug Liberation
  • Hyaluronic Acid / administration & dosage
  • Hyaluronic Acid / chemistry*
  • Loratadine / chemistry*
  • Loratadine / pharmacokinetics*
  • Male
  • Nanostructures / administration & dosage
  • Nanostructures / chemistry*
  • Nanostructures / ultrastructure
  • Particle Size
  • Rats
  • Surface Properties
  • Suspensions / administration & dosage
  • Suspensions / chemistry*
  • Viscosity

Substances

  • Adhesives
  • Suspensions
  • Loratadine
  • Hyaluronic Acid